These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26233533)

  • 1. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    Shiota M; Yokomizo A
    Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer: Enzalutamide--differential cross resistance with taxanes.
    Fenner A
    Nat Rev Urol; 2015 Feb; 12(2):64. PubMed ID: 25534993
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
    van Soest RJ; de Wit R; van Weerden WM
    Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Caffo O; Maines F; Veccia A
    Eur Urol; 2015 Dec; 68(6):e132-3. PubMed ID: 26320376
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Lu K
    Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711
    [No Abstract]   [Full Text] [Related]  

  • 8. Is in vitro-acquired resistance to enzalutamide a useful model?
    Buonerba C; Di Lorenzo G
    Future Oncol; 2014 Dec; 10(16):2551-3. PubMed ID: 25531044
    [No Abstract]   [Full Text] [Related]  

  • 9. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
    Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.
    Thomson D; Charnley N; Parikh O
    Eur J Cancer; 2014 Mar; 50(5):1040-1. PubMed ID: 24462374
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.
    Lorente D; Bianchini D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; De Bono JS
    Eur J Cancer; 2014 Mar; 50(5):1042-3. PubMed ID: 24433842
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono J
    Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Christoph A. Von Klot, Markus A. Kuczyk, Axel S. Merseburger. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014;65:258-9: Enzalutamide withdrawal syndrome: fact or fiction?
    Schrader AJ; Schrader MG; Cronauer MV
    Eur Urol; 2014 Feb; 65(2):e22-3. PubMed ID: 24210913
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: Niclosamide jumps the hurdle of enzalutamide resistance.
    Fenner A
    Nat Rev Urol; 2014 Aug; 11(8):424. PubMed ID: 24980198
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56. AR-V7 Testing: What's in it for the Patient?: Estimating the Clinical Utility of Blood-based AR-V7 Testing in Prostate Cancer.
    Luo J; Luber B; Wang H; Antonarakis ES
    Eur Urol; 2017 Dec; 72(6):e170-e171. PubMed ID: 28693939
    [No Abstract]   [Full Text] [Related]  

  • 17. New treatment options in castration-resistant prostate cancer.
    Armstrong AJ
    J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):690-3. PubMed ID: 25995432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.
    Hotte SJ
    Future Oncol; 2017 Feb; 13(4):369-379. PubMed ID: 27712093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of taxanes on androgen receptor signaling.
    Bai S; Zhang BY; Dong Y
    Asian J Androl; 2019; 21(3):249-252. PubMed ID: 29900882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
    Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
    Eur Urol; 2017 Apr; 71(4):e107-e108. PubMed ID: 27647434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.